Dulaglutide vs GHRP-2
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideGrowth Hormone Peptides
GHRP-2- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- GHRP-2 is a potent synthetic hexapeptide that stimulates growth hormone release by activating ghrelin receptors in the pituitary and hypothalamus. It produces one of the strongest GH pulses among GHRPs, though unlike Ipamorelin it does cause modest increases in cortisol and prolactin.
- Half-Life
- ~5 days
- 15–60 minutes
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 100–300 mcg
- Frequency
- Once weekly
- 2–3 times daily
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Strong GH pulse stimulation
- Increased IGF-1 levels
- Enhanced muscle growth and recovery
- Improved fat metabolism
- Better sleep quality
- Increased bone density
- Enhanced appetite (less pronounced than GHRP-6)
- Anti-aging effects via GH axis optimization
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Increased appetite
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Stacks With
- —
- —